Quotient Sciences Header

Quotient Sciences Header

X

Find Approved Drugs for Genetic Disease in Clinical Development in CANADA

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Apotex Inc.","sponsor":"CHIESI USA INC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox\u00ae (deferiprone)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Apotex Inc."}]

Apotex Inc.

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)

Details:

Chiesi Group expands distribution network via acquisition for worldwide product rights.

Lead Product(s): Deferiprone

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: CHIESI USA INC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 13, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY